Views & Analysis | Perspectives on pharma industry issues

Skip to main content

Friday 2 October 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

R&D

Silhouette of a head with white brain under magnifying glass inside outline, against yellow background

Alzheimer’s: Starting the impossible journey

Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.

Sales & Marketing

Launch excellence concept

Your launch strategy has never met the competition

Will your launch strategy work once it has finally left the meeting room and met the competition?

Oncology

Dr Michael Bauer and Jonah Comstock

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

Digital

AI concept in life sciences, male scientist in the lab in background to digital displays

Beyond AI pilots: Pharma needs AI-native operating models, n...

Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Print

Sponsored

Customer engagement and pharma’s field force future

How healthcare professionals (HCPs) prefer to engage with pharma companies has been changing for some time, and COVID’s digital transformation of society has dramatically accelerated this.<

Views & Analysis

The landscape for UK R&D SMEs post-COVID

The landscape for UK R&D SMEs post-COVID

Big pharma might have dominated COVID headlines with its vaccine drive, but behind the scenes an army of SMEs has enabled the UK to respond swiftly to the pandemic.

R&D

immune-system-1132182_1920 (1) (1)

The host immune response in COVID-19 and beyond

MeMed CEO Dr. Eran Eden explores the relationship between the host immune response and SARS-CoV-2 infection and how technology could help personalise treatment strategies.

Load more results

Sales & Marketing

Sales & Marketing

Launch excellence concept

Your launch strategy has never met the competition

Will your launch strategy work once it has finally left the meeting room and met the competition?

Sales & Marketing

Female HCP in her office on phone holding clipboard of patient information

Sponsored

Commercial Evidence: Turning field intelligence into actiona...

Agentic Call Reports help turn field observations into scalable, actionable insights generating Commercial Evidence.

Digital

Digital

AI concept in life sciences, male scientist in the lab in background to digital displays

Beyond AI pilots: Pharma needs AI-native operating models, n...

Industry must build custom solutions that leverage a pharmaceutical business’ unique assets – including its people.

Digital

Businessman presses power off for AI

Healthcare AI’s off switch needs a budget

An AI system can be cheap to buy and expensive to stop.

Market Access

Market Access

Chinese flag atop pills on black background

Is the next generation of Chinese biotech ready to go global...

Will Chinese biotechs continue to transfer most ex-China rights, or retain their strongest assets and compete internationally themselves?

Market Access

Two business hands outstretched, one weighing cash, the other drugs, for balance

What the revised 340B rebate pilot programme means for pharm...

While the scope of the revised pilot is limited, it may be a harbinger for a broader policy shift.

Editor's Picks

FDA nominee Overton dodges questions on Trump influence

Australia starts probe into AI infiltration of Medicare

Lilly forges $3.35bn alliance with China's InnoCare

Telix to buy radiopharma rival ITM for $1.65bn upfront

Advocacy group pokes holes in Trump's MFN pricing claims

Newsletters and Deep Dive
digital magazine

Get Newsletters

Get in-depth news, opinions, and features on pharma and healthcare sent straight to your inbox

Oncology

Oncology

Dr Michael Bauer and Jonah Comstock

Dr Michael Bauer on Quantro’s mission to drug the “undruggab...

Jonah Comstock reunited with Dr Michael Bauer, CEO of Quantro Therapeutics, at LSX 2026 to discuss the company's progress.

Oncology

Cancer cell and T-cells

In vivo CAR-T can solve the delivery problem – but solid tum...

A new generation of in vivo CAR-T cell technologies promises to remove some of the biggest practical barriers to conventional cell therapy.

Oncology

T-cells in action

Unlocking the scalability of allogeneic CAR-T

Allogeneic CAR-T, built from healthy donor T-cells, offers a different path toward scale, accessibility, and consistency.

Patients

Patients

Union Jack on pill, one of many scattered on aqua surface

Rare diseases, real opportunity: Why the UK’s next challenge...

The UK has the science, the talent, and the investment. The next step is ensuring that innovation translates into timely patient impact.

Patients

oral GLP-1

Maintenance: The underexamined half of the GLP-1 story

GLP-1 treatments have historically had an exit problem, as appetite suppression stops when the medication stops.

Patients

World Patient Safety Day 17th September

Why patient safety doesn't end at approval

Once a treatment becomes available to the public, protecting patient safety remains a priority throughout its time on the market.

R&D

R&D

Silhouette of a head with white brain under magnifying glass inside outline, against yellow background

Alzheimer’s: Starting the impossible journey

Not long ago, the prospect of having disease-modifying treatments for Alzheimer’s disease (AD) seemed almost a flight of fancy.

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

HCPs in CPD session

Why every healthcare breakthrough creates a new education ch...

Patients will only benefit from a health breakthrough if HCPs and the systems around them are able to put it into practice.

Editor's Picks

FDA nominee Overton dodges questions on Trump influence

Australia starts probe into AI infiltration of Medicare

Lilly forges $3.35bn alliance with China's InnoCare

Telix to buy radiopharma rival ITM for $1.65bn upfront

Advocacy group pokes holes in Trump's MFN pricing claims

News

Novartis taps China's Abogen for autoimmunity TCE

Novartis taps China's Abogen for autoimmunity TCE

Novartis has added a T-cell engager developed by China's Abogen Biosciences for autoimmune disorders in a deal that could be worth over $7.5bn.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement

Sponsored

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company